ArticleShock (Augusta, Ga.)2026
SMAD7 Downregulation Promotes Ferroptosis in Pulmonary Arterial Hypertension Via the TGF-β1-SMAD2/3 Pathway.
Article in Shock (Augusta, Ga.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundIn pulmonary arterial hypertension (PAH), ferroptosis could influence vascular remodeling by affecting the pulmonary artery endothelial cells (PAECs). However, the underlying pathogenic mechanisms of ferroptosis in PAH and its impact on the pulmonary vascular cellular landscape remain poorly understood.
methodsIn this study, we integrated single-cell transcriptomic sequencing, proteomics, and summary-data-based Mendelian randomization to investigate the regulatory mechanisms of ferroptosis in PAH. Our findings were validated using monocrotaline-induced PAH rat models and hypoxia-induced PAEC models.
resultsSingle-cell transcriptomic analysis revealed an increased propensity for ferroptosis in PAECs, while general capillary endothelial cells showed enhanced proliferative tendencies. Integrated analysis of single-cell transcriptomics, proteomics, and summary-data-based Mendelian randomization suggested that SMAD7 may serve as a negative regulator of ferroptosis in PAECs. Additionally, experiments conducted both in vitro and in vivo showed that reducing SMAD7 expression enhanced ferroptosis in PAECs, whereas SMAD7 overexpression alleviated ferroptosis and pulmonary vascular remodeling, potentially by blocking the transforming growth factor-beta -1-SMAD2/3 signaling pathway.
conclusionsThis study provides preliminary evidence that SMAD7 may negatively regulate ferroptosis via the transforming growth factor-beta -1-SMAD2/3 pathway in PAECs and thereby contribute to pulmonary vascular remodeling in PAH. These findings highlight SMAD7 as a potential therapeutic target for PAH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.